Charleen Jue
About Charleen Jue
Charleen Jue serves as the Senior Vice President of Clinical Development Operations at Nektar Therapeutics, where she oversees clinical operations and strategic development. With over twenty years of experience in the biotechnology sector, she specializes in clinical programs for hematology, oncology, and pain management.
Current Role at Nektar Therapeutics
Charleen Jue serves as the Senior Vice President of Clinical Development Operations at Nektar Therapeutics. In this role, she contributes to the strategic development of clinical programs and directs all clinical operations activities. Her responsibilities include developing and facilitating collaborations with academic centers and Contract Research Organizations (CROs). She has been with Nektar Therapeutics since 2019.
Previous Experience at Nektar Therapeutics
Charleen Jue has held multiple positions at Nektar Therapeutics. She worked as Vice President of Clinical Operations from 2010 to 2014, where she focused on clinical program development. Additionally, she served as Vice President of Clinical Development Operations for a brief period in 2018. Her cumulative experience at Nektar Therapeutics spans over four years.
Experience at GENFIT
Before her tenure at Nektar Therapeutics, Charleen Jue was the Vice President of Clinical Operations at GENFIT from 2016 to 2018. In this position, she oversaw clinical operations and contributed to the development of clinical programs within the organization.
Education and Expertise
Charleen Jue earned a Bachelor of Applied Science (BASc) in General Biology from New Mexico State University, where she studied from 1982 to 1986. With over twenty years of experience in the biotechnology sector, she is knowledgeable in the development and conduct of clinical programs, particularly in hematology, oncology, and pain management. She has experience in developing global clinical programs and conducting all phases of clinical research.
Background
Charleen Jue has a robust background in clinical development operations within the biotechnology industry. Her career spans over two decades, during which she has developed therapeutics and managed clinical programs. Her expertise includes collaboration with academic institutions and CROs, enhancing the efficiency of clinical research initiatives.